N-Acetylcysteine for Nonsuicidal Self-Injurious Behavior in 3 Adults With Williams Syndrome: A Case Series.

IF 2.9 3区医学 Q2 PHARMACOLOGY & PHARMACY

Journal of Clinical Psychopharmacology Pub Date : 2025-02-27 DOI:10.1097/JCP.0000000000001976

Hagar Kandel, Ava R Cruz, Robyn P Thom, Christopher J McDougle

{"title":"N-Acetylcysteine for Nonsuicidal Self-Injurious Behavior in 3 Adults With Williams Syndrome: A Case Series.","authors":"Hagar Kandel, Ava R Cruz, Robyn P Thom, Christopher J McDougle","doi":"10.1097/JCP.0000000000001976","DOIUrl":null,"url":null,"abstract":"Background: Williams syndrome (WS) is a genetic disorder that results from a microdeletion of 25 to 27 genes on chromosome 7q11.23. Individuals with WS often exhibit comorbid neuropsychiatric symptoms, especially anxiety. To our knowledge, nonsuicidal self-injurious behavior (NSSIB) has not been reported in WS. N-acetylcysteine (NAC) is a safe and readily available drug that may modulate glutamate activity in the brain. NAC is effective for treating various neuropsychiatric symptoms and disorders. There are limited reports in the literature where NAC has been used to treat NSSIB effectively, but none in WS.Methods: This report describes using NAC to treat NSSIB in 3 adults with WS.Findings: Nonsuicidal self-injurious behavior was successfully treated in 3 adults with WS using NAC in doses ranging from 2400 to 3600 mg a day, resulting in significant improvement in their daily functioning. Additionally, NAC was well tolerated.Conclusions: NAC was effective for treating NSSIB in 3 adults with WS. By addressing these challenging behaviors, NAC offers a promising pharmacological intervention that can significantly improve the quality of life for patients with WS who engage in NSSIB. Further research and clinical trials are necessary.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/JCP.0000000000001976","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Williams syndrome (WS) is a genetic disorder that results from a microdeletion of 25 to 27 genes on chromosome 7q11.23. Individuals with WS often exhibit comorbid neuropsychiatric symptoms, especially anxiety. To our knowledge, nonsuicidal self-injurious behavior (NSSIB) has not been reported in WS. N-acetylcysteine (NAC) is a safe and readily available drug that may modulate glutamate activity in the brain. NAC is effective for treating various neuropsychiatric symptoms and disorders. There are limited reports in the literature where NAC has been used to treat NSSIB effectively, but none in WS.

Methods: This report describes using NAC to treat NSSIB in 3 adults with WS.

Findings: Nonsuicidal self-injurious behavior was successfully treated in 3 adults with WS using NAC in doses ranging from 2400 to 3600 mg a day, resulting in significant improvement in their daily functioning. Additionally, NAC was well tolerated.

Conclusions: NAC was effective for treating NSSIB in 3 adults with WS. By addressing these challenging behaviors, NAC offers a promising pharmacological intervention that can significantly improve the quality of life for patients with WS who engage in NSSIB. Further research and clinical trials are necessary.

查看原文本刊更多论文

n -乙酰半胱氨酸对威廉斯综合征3例成人非自杀自伤行为的影响

背景介绍威廉姆斯综合征（WS）是一种遗传性疾病，由染色体 7q11.23 上 25 至 27 个基因的微缺失引起。威廉姆斯综合征患者通常合并神经精神症状，尤其是焦虑。据我们所知，还没有关于 WS 患者非自杀性自伤行为（NSSIB）的报道。N-乙酰半胱氨酸（NAC）是一种安全易得的药物，可调节大脑中谷氨酸的活性。NAC 可有效治疗各种神经精神症状和疾病。文献中关于使用 NAC 有效治疗 NSSIB 的报道有限，但在 WS 中却没有报道：本报告介绍了使用 NAC 治疗 3 名成人 WS 患者的 NSSIB：3 名成人 WS 患者使用 NAC 成功治疗了非自杀性自残行为，每天的剂量从 2400 毫克到 3600 毫克不等，从而显著改善了他们的日常功能。此外，NAC的耐受性良好：结论：NAC 可有效治疗 3 名成人 WS 患者的 NSSIB。通过解决这些具有挑战性的行为，NAC提供了一种很有前景的药物干预方法，可以显著改善有NSSIB行为的WS患者的生活质量。有必要开展进一步的研究和临床试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Psychopharmacology 医学-精神病学

CiteScore

4.00

自引率

3.40%

发文量

231

审稿时长

4-8 weeks

期刊介绍： Journal of Clinical Psychopharmacology, a leading publication in psychopharmacology, offers a wide range of articles reporting on clinical trials and studies, side effects, drug interactions, overdose management, pharmacogenetics, pharmacokinetics, and psychiatric effects of non-psychiatric drugs. The journal keeps clinician-scientists and trainees up-to-date on the latest clinical developments in psychopharmacologic agents, presenting the extensive coverage needed to keep up with every development in this fast-growing field.